Skip to main content

Table 3 Calcium assessments of premenopausal female patients with Graves' disease compared to both healthy controls and patients with Hashimoto's thyroiditis on stable levothyroxine replacement.

From: Can bone loss be reversed by antithyroid drug therapy in premenopausal women with Graves' disease?

 

Controls

Graves' disease Months after diagnosis

Hashimoto's thyroiditis

Study points (months)

 

Baseline

3

18 ± 3

36 ± 3

 

Number

19

32

18

PTH¤ (pg/ml)

39

23NS

32*

39*

-

32 NS

 

(22-72)

(16-34)

(22-46)

(25-59)

 

(13-83)

Calcium (mmol/L)

2.23

2.42##

2.30**

2.27**

2.31**

2.23 NS

 

(2.19-2.28)

(2.38-2.46)

(2.27-2.34)

(2.24-2.29)

(2.28-2.35)

(2.24-2.35)

Ca2+ (mmol/L)

1.21

1.32##

1.23**

1.24**

1.25**

1.26 NS

 

(1.20-1.23)

(1.31-1.34)

(1.22-1.26)

(1.23-1.25)

(1.23-1.26)

(1.16-1.38)

Alkaline phosphatase

136

223##

251##

180**,#

160**

150NS

(U/I)

(120-155)

(199-249)

(218-288)

(159-204)

(141-180)

(126-179)

Urinary Calcium (mmol)

4.1

5.2NS

2.8**

3.6 NS

4.0 NS

3.4 NS

 

(2.9-5.9)

(4.1-6.5)

(2.2-3.7)

(2.9-4.5)

(3.1-5.2)

(2.6-4.5)

Creatinine Cl. (ml/sec)

1.3

1.2NS

1.3NS

1.2 NS

1.3 NS

1.1 NS

 

(1.2-1.5)

(1.1-1.4)

(1.2-1.4)

(1.1-1.4)

(1.1-1.5)

(1.0-2.3)

  1. Data are expressed as antilog mean (CI 95%) and significance is marked as * = p < 0.05, ** = p < 0.005 when compared to baseline and marked differently as # = p < 0.05, ## = p < 0.005 when normal controls were compared to baseline data for patient with Graves' diseases or patient with Hashimoto disease. NS = non-significant. ¤ = N varied from 4-11.